Effects of Light Treatment During Sleep on Young Men

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00796939
Recruitment Status : Completed
First Posted : November 24, 2008
Last Update Posted : April 10, 2015
National Institute of Mental Health (NIMH)
Information provided by:
University of California, San Diego

Brief Summary:
This study will determine if green light exposure during sleep is effective in reducing mild depression symptoms in young men.

Condition or disease Intervention/treatment Phase
Depression Device: Green light mask Device: Red Light Mask Not Applicable

Detailed Description:

The circadian rhythm is the human body's internal clock. It affects sleeping and wakefulness patterns. Some scientists theorize that a disruption of circadian rhythms, or other circadian abnormalities, can cause a depressed state. Light received through the eyes can alter the circadian rhythm, and sustained exposure to artificial bright light during the last half of usual sleep time can change the phase of the circadian rhythm. Several studies have found that exposure to bright white light in the morning hours is an effective treatment for depression, especially during the first week of depression treatment. Other studies have shown that green or blue light is preferable to yellow or red light in depression treatment. This study will expose young men to different types of light during the last part of their sleep cycle to determine whether the treatment is safe and tolerable and whether it reduces mood disturbance and depression. The study will also determine the light's effect on the production of luteinizing hormone (LH) and testosterone, hormones that may play a role in depression.

Participation in this study will last 15 days. At the beginning of the study, participants will be provided with study materials and instructed in their use. These materials will include a wrist actigraph, which is a sleep and wakefulness monitoring device similar to a wristwatch; a binder containing instructions, questionnaires, and forms; and a light mask. Participants will be randomly assigned to receive a light mask with either intense green or dim red light. Participants will wear the wrist actigraph throughout the study. For the first 3 days of the study, participants will sleep normally and fill out questionnaires and a sleep diary. The questionnaires will measure mood, sleepiness, sleep quality, treatment effects, and sleep time preference. The sleep diary will be a record of time spent sleeping, time it takes to fall asleep, number of times waking during the night, and similar measures. Starting on the third night, participants will wear the light mask when sleeping. Every day participants will fill out the questionnaires and sleep diary, and they will contact the study investigators to ensure compliance and to ask any questions. Participants will also provide saliva and urine samples once at the beginning and once at the end of the study. These samples will be used to test for testosterone and LH, respectively.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Randomized, Placebo-Controlled Trial of Short Wavelength Light Administered Just Prior to Waking in Young Men
Study Start Date : March 2006
Actual Primary Completion Date : October 2006
Actual Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Green Light Mask Device: Green light mask
Participants will receive approximately 10,000 lux from green light-emitting diodes.

Placebo Comparator: Red light mask Device: Red Light Mask
Participants will receive approximately 0.5 lux from white light-emitting diodes covered by a red gel.

Primary Outcome Measures :
  1. Safety, measured through the Systematic Assessment for Treatment Emergent Effects (SAFTEE) questionnaire [ Time Frame: Measured on Days 3 and 15 ]
  2. Tolerability, measured through compliance reports [ Time Frame: Measured daily for the length of the study ]
  3. Mood disturbance, measured on the Quick Inventory of Depressive Symptomology-Self Report (QIDS-SR) [ Time Frame: Measured on Days 3 and 15 ]

Secondary Outcome Measures :
  1. Sleep diary [ Time Frame: Measured daily for the duration of the study ]
  2. Mood visual analog scale [ Time Frame: Measured daily for the duration of the study ]
  3. Luteinizing hormone, measured through urinalysis [ Time Frame: Measured on Days 3 and 13 ]
  4. Testosterone, measured through saliva analysis [ Time Frame: Measured on Days 3 and 13 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   25 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Exclusion Criteria:

  • Presence of clinical depression
  • Presence of a sleep disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00796939

United States, California
La Jolla, California, United States, 92093
Sponsors and Collaborators
University of California, San Diego
National Institute of Mental Health (NIMH)

Responsible Party: Michael Grandner, PhD, University of California, San Diego Identifier: NCT00796939     History of Changes
Other Study ID Numbers: R01MH068545 ( U.S. NIH Grant/Contract )
R01MH068545 ( U.S. NIH Grant/Contract )
First Posted: November 24, 2008    Key Record Dates
Last Update Posted: April 10, 2015
Last Verified: April 2015

Keywords provided by University of California, San Diego:
Delayed Sleep Phase Syndrome